Help us transform the future of cancer treatment

Centre for Cancer Drug Discovery Appeal
Donor naming opportunities
Thank you for considering our fundraising appeal for our Centre for Cancer Drug Discovery.

As you know, the ICR is a leader in this field, having discovered more new treatments for cancer than any other academic institution globally. Men all over the world are living longer thanks to our prostate cancer drug, abiraterone; and many women are benefiting from the ovarian cancer therapy, olaparib, which is underpinned by ICR research.

Now we want to make a further step change towards transforming patients’ lives. Our aim is to create many more, smarter and kinder treatments, including for rarer tumours. Cancer is clever, and can adapt and evolve to evade treatment. At the ICR, we have a superb body of talent and knowledge in cancer evolution. We want to combine this expertise with our drug discoverers, our big data specialists and our top class clinicians in a cutting-edge, collaborative building – to deliver solutions for cancer drug resistance through excellent team science.

The Centre – based in south London – is a £70m build, and we now have less than £20m to raise. If you can give to our appeal, we’d be delighted to acknowledge your support through the naming opportunities set out in this brochure.

Please help us if you can.

Professor Paul Workman FRS
Chief Executive and President
Naming of the Centre for Cancer Drug Discovery

£15m

The ICR has a long history in philanthropy, going back to its foundation in 1909. Many of our discoveries have been made possible thanks to the generosity of donors and benefactors who believe in our research and share our passion for improving cancer patients’ lives. So we hope you will join us in our latest capital venture, the Centre for Cancer Drug Discovery.

We would be delighted to recognise a gift of £15m by offering naming of the Centre for Cancer Drug Discovery. In this state-of-the-art building, at the cutting-edge of cancer research, we intend to make an historic step change in cancer therapy.
Biology Unit: £3m
An extensive laboratory space in which our biologists will identify targets within cancer cells against which drugs are most likely to be successful.

Café: £1m
Prominently-positioned near the Centre entrance, the café will offer space for researchers to meet for informal discussion, potentially sowing the seeds for new creative collaboration.

Centre for Evolution and Cancer: £2m
Embedded within our biology facilities will be our evolutionary specialists dedicated to understanding how cancer adapts and evolves to evade treatment.

6 Discovery Units: £100k - £250k
Providing modern, 21st century wet lab space, organised as individual bays, for each research team.

7 Team Leader Offices: £100k
Office space for the leader of each research group.

“We now understand how cancers evolve, adapting to the environments within our bodies and side stepping the drugs designed to halt their progress. To find better treatments we need to build on this new knowledge and expose cancer to therapies that can stop evolutionary resilience.”

Professor Mel Greaves FRS
Director, Centre for Evolution and Cancer
Biology Suite: £5m
Encompassing the entire first floor, this suite will provide our biologists with laboratories in which to identify new drug targets, together with write-up areas and collaborative and breakout spaces to facilitate team science.

Protein Production Laboratory: £250k
A dedicated lab for studying the complex interplay of proteins responsible for driving the development, growth and spread of cancers.

Analytical Technology & Screening Laboratory: £250k
A specialist facility for running high throughput screening of cancer drug targets and characterising the “hits” obtained.

6 Discovery Units: £100k - £250k
Providing modern, 21st century wet lab space, organised as individual bays, for each research team.

2 Meeting Rooms: £100k
More formal spaces for scientists to discuss the progression of their research programmes.

8 Team Leader Offices: £100k
Office space for the leader of each research group.

Collaboration Hub: £100k
Breakout space in which to foster cross-disciplinary collaboration and creativity.

“The Centre for Cancer Drug Discovery will provide us with the optimum environment for creative collaboration between scientific disciplines so that we can accelerate our work to identify novel ways to treat cancer.”
Dr Olivia Rossanese
Head of Biology, Cancer Therapeutics
“From many years in research – in industry and academia – I firmly believe in the power of “team science”. The new Centre will enable us to build our capacity and to bring together multi-disciplinary teams of world-leading expertise. By working in this way, we will have a significant impact on the problem of cancers evolving to cause drug resistance.”

Professor Raj Chopra
Head of Cancer Therapeutics
3

Medicinal Chemistry Unit: £3m
An extensive chemistry facility in which we will design and synthesise innovative new cancer drugs.

Computational Laboratory: £250k
A dedicated space for our bioinformatics specialists.

In silico Laboratory: £250k
Using cutting-edge computational techniques to design more effective cancer drugs.

14 discovery units: £100k - £250k
Providing modern, 21st century wet lab space, organised as individual bays, for each research team.

Glass Meeting Room: £200k
A particularly stunning meeting room on the top floor of the new Centre.

3D Visualisation Suite: £500k
Housing the latest 3-D computer imaging technologies to aid drug design.

5 Team Leader Offices: £100k
Office space for the leader of each research group.

14 discovery units: £100k - £250k
Providing modern, 21st century wet lab space, organised as individual bays, for each research team.

“Incredibly exciting that young scientists and clinicians like me will have the opportunity to learn from the best in this amazing space, so that we can then go on to discover the cancer therapies of the future.”

Ellen Watts
3rd Year PhD student, Cancer Therapeutics
Please help us to transform the future of cancer treatment by naming a space in our Centre for Cancer Drug Discovery.

All naming recognition will be for a period of 25 years and subject to formal written agreement between ICR and the donor.

The floor plans shown in this document are illustrative and not precisely to scale.

Message from Sue Vincent, Cancer Survivor

“I was diagnosed with advanced ovarian cancer in 2007. After initial gruelling but successful chemotherapy, my cancer returned in 2010 and it had spread to three parts of my body. I was looking at months rather than years to live.

Then I was offered a place on a clinical trial for a pioneering drug called olaparib, the discovery and development of which was underpinned by research at the ICR.

I have been taking olaparib for seven years. It has meant I’ve seen four beautiful grandchildren born. It has allowed me to go back to the gym, to build a successful business and given me a quality of life that I could only dream of.

So I want to say thank you from the bottom of my heart, for supporting the ICR’s research and helping people like me. Olaparib has given me my life back.”
Contact the ICR

If you would like to have further discussion with us about our Centre for Cancer Drug Discovery capital appeal and donor naming opportunities, please contact:

Lara Jukes, Director of Development
lara.jukes@icr.ac.uk

Thomas Bland, Deputy Director, Trusts and Foundations
thomas.bland@icr.ac.uk

Hannah Joyce, Deputy Director, Philanthropy
hannah.joyce@icr.ac.uk